Induction of a Robust Humoral Response using HIV-1 VLPMPER-V3 as a Novel Candidate Vaccine in BALB/c Mice

Author(s): Fatemeh Tohidi, Seyed Mehdi Sadat*, Azam Bolhassani, Ramin Yaghobi, Mona Sadat Larijani.

Journal Name: Current HIV Research

Volume 17 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Several approaches have not been successful to suppress HIV (Human immunodeficiency virus) infection among infected individuals or to prevent it yet. In order to expand strong HIV specific humoral and cellular responses, Virus-like particles (VLPs) as potential vaccines show significant increase in neutralizing antibodies secretion, T-cell count and also secretion of cytokines.

Objective: This study aimed at immunological evaluation of VLPs harboring high copy of MPERV3 in BALB/c mice.

Methods: Female BALB/c mice were immunized with homologous and heterologous primeboosting regimens of HIV-1 VLPMPER-V3. Their immune responses were evaluated for humoral responses (Total IgG and IgG isotyping) and cellular responses (IFN-γ, IL-5 secretion, in vitro CTL assay and T cell proliferation) and compared in immunized mice.

Results: The data showed robust induction of humoral response in mice groups which received different regimens of VLP. Furthermore, analysis of cytokine profile indicated that the highest IL-5 secretion was related to VLP+M50 group and confirmed the dominance of Th2 immunity in this group.

Conclusion: This study showed that VLP MPER-V3 as a potential vaccine candidate has the potency as an effective prophylactic vaccine and this finding guarantees further investigations to achieve a promising HIV-1 vaccine candidate.

Keywords: HIV, immunological evaluation, vaccine, BaALB/c, VLP MPER-V3, VLP+M50.

[1]
HIV/AIDS JUNPo. UNAIDS. 2017.
[2]
Sosa D, Jayant DR, Kaushik A, Nair M. Current status of human immunodeficiency virus vaccine. Vaccin Res Open J 2016; 1(1): e3-5.
[3]
Crisci E, Barcena J, Montoya M. Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 2012; 148(3-4): 211-25.
[4]
Trovato M, D’Apice L, Prisco A, De Berardinis P. HIV vaccination: A roadmap among advancements and concerns. Int J Mol Sci 2018; 19(4): 1241.
[5]
Rumbwere Dube BN, Marshall TP, Ryan RP, Omonijo M. Predictors of human immunodeficiency virus (HIV) infection in primary care among adults living in developed countries: a systematic review. Syst Rev 2018; 7(1): 82.
[6]
Zhuang GZM. Construction and immunological evaluation of immunostimulatory nanocomposites with vaccine potential. J Infect Dis Ther 2017; 5(5): 1-4.
[7]
Munson P, Liu Y, Bratt D, et al. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. Hum Vaccin Immunother 2018; 14(7): 1820-31.
[8]
Maxmen A. Promising HIV vaccines could stall without coordinated research. Nature 2018; 555(7694): 17-8.
[9]
Gao Y, McKay PF, Mann JFS. Advances in HIV-1 Vaccine Development. Viruses 2018; 10(4): 167.
[10]
Tissot AC, Renhofa R, Schmitz N, et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010; 5(3): e9809.
[11]
Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines 2010; 9(10): 1149-76.
[12]
Bayon E, Morlieras J, Dereuddre-Bosquet N, et al. Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates. NPJ Vaccines 2018; 3(1): 46.
[13]
Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326(5950): 285-9.
[14]
Moyo N, Vogel AB, Buus S, et al. Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA. Mol Ther Methods Clin Dev 2019; 12: 32-46.
[15]
Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329(5993): 856-61.
[16]
Andrabi R, Williams C, Wang X-H, et al. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. Virology 2013; 439(2): 81-8.
[17]
Visciano ML, Diomede L, Tagliamonte M, et al. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine 2011; 29(31): 4903-12.
[18]
Gray GE, Laher F, Lazarus E, Ensoli B, Corey L. Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol 2016; 17: 104-9.
[19]
Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 2008; 381(2): 251-60.
[20]
Gazarian KG, Palacios-Rodriguez Y, Gazarian TG, Huerta L. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features. Mol Immunol 2013; 54(2): 148-56.
[21]
Quan FS, Sailaja G, Skountzou I, et al. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 2007; 25(19): 3841-50.
[22]
Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clinical microbiology reviews 2004; 17(2): 370-89.
[23]
Koff WC. A shot at AIDS. Curr Opin Biotechnol 2016; 42: 147-51.
[24]
Pawlak EN, Dikeakos JD. HIV-1 Nef: a master manipulator of the membrane trafficking machinery mediating immune evasion. Biochimica et Biophysica Acta (BBA) -. General Subjects 2015; 1850(4): 733-41.
[25]
Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 2015; 66: 423-37.
[26]
Tohidi F, Sadat SM, Bolhassani A, Yaghobi R. Construction and production of HIV-VLP harboring MPER-V3 for potential vaccine study. Curr HIV Res 2017; 15(6): 434-9.
[27]
Sadat SMZR, Aghasadeghi MR, Vahabpour R, et al. Application of SCR priming VLP boosting as a novel vaccination strategy against HIV-1. Curr HIV Res 2011; 9(3): 140-7.
[28]
Kuerten S, Nowacki TM, Kleen TO, et al. Dissociated production of perforin, granzyme B, and IFN-gamma by HIV-specific CD8(+) cells in HIV infection. AIDS Res Hum Retroviruses 2008; 24(1): 62-71.
[29]
Chapman R, Jongwe TI, Douglass N, Chege G, Williamson AL. Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice. PLoS One 2017; 12(3): e0173352.
[30]
Cheong ChCJ, Vitale L. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody. Blood 2010; 116: 3828-40.
[31]
Barouch DH. OBK, Simmons NL. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16: 319-23.
[32]
Munier CM, Andersen CR, Kelleher AD. HIV vaccines: progress to date. Drugs 2011; 71(4): 387-414.
[33]
Achour A, Biquard J-M, Krsmanovic V, et al. Induction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptide. PLoS One 2007; 2(11): e1214.
[34]
Maggiorella MT, Sernicola L, Crostarosa F, et al. Multiprotein genetic vaccine in the SIV‐Macaca animal model: a promising approach to generate sterilizing immunity to HIV infectio. J Med Primatol 2007; 36: 180-94.
[35]
Buonaguro L, Tagliamonte M, Visciano ML, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for HIV. Expert Rev Vaccines 2013; 12(2): 119-27.
[36]
Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013; 53(1): 92-107.
[37]
Wang JW, Roden RBS. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Exp Rev Vaccin 2013; 12(2): 129-41.
[38]
Chroboczek J, Szurgot I, Szolajska E. Virus-like particles as vaccine. Acta Biochim Pol 2014; 61(3): 531-9.
[39]
Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002; 32(3): 818-25.
[40]
Zhao C, Ao Z, Yao X. Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines 2016; 4(1): pii:E2.
[41]
Chen Y, Wang S, Lu S. DNA Immunization for HIV Vaccine Development. Vaccines 2014; 2(1): 138-59.
[42]
Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 2014; 12: 750.
[43]
Fomsgaard A. Therapeutic HIV peptide vaccine. Methods Mol Biol 2015; 1348: 351-7.
[44]
Mona Sadat L, Seyed Mehdi S, Azam B, et al. In silico design and immunologic evaluation of HIV-1 p24-Nef fusion protein to approach a therapeutic vaccine candidate. Curr HIV Res 2018; 16(5): 322-37.
[45]
Milani A, Bolhassani A, Shahbazi S, et al. Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity. Immunol Lett 2017; 191: 16-22.
[46]
Benen TD, Tonks P, Kliche A, et al. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci 2014; 21: 79.
[47]
Letvin NL, Robinson S, Rohne D, et al. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. J Virol 2001; 75(9): 4165-75.
[48]
Ruprecht CR, Krarup A, Reynell L, et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. The Journal of experimental medicine 2011; 208(3): 439-54.
[49]
Gangadhara S, Kwon YM, et al. Vaccination with combination DNA and virus-like particles enhances humoral and cellular immune responses upon boost with recombinant modified vaccinia virus ankara expressing human immunodeficiency virus envelope proteins. Vaccines 2017; 5(52): 2-14.
[50]
Bolhassani A, Kardani K, Vahabpour R, et al. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses. Immunol Lett 2015; 168(2): 366-73.
[51]
Matthaei KI, Foster P, Young IG. The role of interleukin-5 (IL-5) in vivo : studies with IL-5 deficient mice. Mem Inst Oswaldo Cruz 1997; 92(Suppl. 2): 63-8.
[52]
Mailliard RB, Smith KN, Fecek RJ, et al. Selective induction of CTL helper rather than killer activity by natural epitope variants promotes dendritic cell-mediated HIV-1 dissemination. J Immunol 2013; 191(5): 2570-80.
[53]
Genescà M. Characterization of an effective CTL response against HIV and SIV infections. J Biomed Biotechnol 2011; 2011: 103924.
[54]
Demers KR, Reuter MA, Betts MR. CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunol Rev 2013; 254(1): 190-206.
[55]
Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21(3): 346-51.
[56]
Mahdavi M, Ebtekar M, Hassan ZM, et al. An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses. Int J Mol Cell Med 2015; 4(4): 218-26.
[57]
Kadkhodayan S, Jafarzade BS, Sadat SM, et al. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model. Immunol Lett 2017; 188: 38-45.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 1
Year: 2019
Page: [33 - 41]
Pages: 9
DOI: 10.2174/1570162X17666190306124218
Price: $65

Article Metrics

PDF: 39
HTML: 10